Market Overview

Omnicell: Q3 Earnings Insights


Shares of Omnicell (NASDAQ:OMCL) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 21.05% year over year to $0.60, which beat the estimate of $0.49.

Revenue of $213,699,000 decreased by 6.60% year over year, which beat the estimate of $208,460,000.


Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $1,015,000,000 and $1,045,000,000.

Conference Call Details

Date: Oct 27, 2020

Time: 04:30 PM

ET Webcast URL:

Recent Stock Performance

52-week high: $94.85

Company's 52-week low was at $54.24

Price action over last quarter: Up 17.81%

Company Description

Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.


Related Articles (OMCL)

View Comments and Join the Discussion!

Posted-In: Earnings